Concepedia

Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

Ignacio Durán, Joan Carles, Iurie Bulat, Peter Hellemans, Anna Mitselos, Peter Ward, James Jiao, Danielle Armas, Caly Chien

Clinical Pharmacokinetics · 2020 · 48 citations · 22 references

DOIFull text

Open access

Abstract

Co-administration of apalutamide with CYP3A4, CYP2C19, CYP2C9, P-gp, BCRP or OATP1B1 substrates may cause loss of activity for these medications. Therefore, appropriate mitigation strategies are recommended.

References

22

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

Kim N., Neeraj Agarwal, Anders Bjartell et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

Matthew R. Smith, Fred Saad, Simon Chowdhury et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text

OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine

Mirjana Cvetković, Brenda F. Leake, Martin F. Fromm et al. · Drug Metabolism and Disposition · 1999 · 593 citations

The effect of rifampin administration on the disposition of fexofenadine

M HAMMAN · Clinical Pharmacology & Therapeutics · 2001 · 202 citations

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism.

Tommy Andersson, John O. Miners, ME Veronese et al. · British Journal of Clinical Pharmacology · 1994 · 145 citations · Full text